About Novartis AG
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: NVS
- Previous Close: $77.28
- 50 Day Moving Average: $73.82
- 200 Day Moving Average: $75.00
- 52-Week Range: $2,374,059,000.00 - $66.93
- Trailing P/E Ratio: 27.60
- Foreward P/E Ratio: 14.83
- P/E Growth: 3.23
- Market Cap: $183.47B
- Outstanding Shares: 2,374,059,000
- Beta: 0.73
- Net Margins: 13.80%
- Return on Equity: 15.37%
- Return on Assets: 8.57%
Companies Related to Novartis AG:
- Debt-to-Equity Ratio: 0.24%
- Current Ratio: 1.12%
- Quick Ratio: 0.84%
What is Novartis AG's stock symbol?
Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?
Novartis AG announced an annual dividend on Friday, January 27th. Investors of record on Friday, March 3rd will be paid a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date of this dividend is Wednesday, March 1st.
Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?
13 brokers have issued twelve-month price targets for Novartis AG's shares. Their predictions range from $85.00 to $92.00. On average, they anticipate Novartis AG's stock price to reach $87.33 in the next twelve months.
What are analysts saying about Novartis AG stock?
Here are some recent quotes from research analysts about Novartis AG stock:
According to Zacks Investment Research, "Novartis’ fourth-quarter 2016 results were mixed with the company beating earnings estimates but missing on revenues. Concurrently, Novartis announced that it is mulling strategic options for Alcon which includes retaining the business or separation via a capital markets transaction such as a spin-off or an initial public offering. Given its dismal performance Alcon seems to be a laggard for quite some time now. The company’s shares have declined more sharply than the Large-Cap Pharmaceutical industry in the last one year. On a positive note, Cosentyx hit $1.1 billion in sales in 2016 thereby becoming a blockbuster drug for Novartis while Entresto is picking up gradually following the positive treatment guidelines in the U.S and Europe and ongoing field force expansion. The oncology portfolio (excluding Gleevec) also looks solid, driven by new assets and Jakavi. We are also impressed by the strong biosimilars portfolio." (1/30/2017)
Citigroup Inc. analysts commented, "The ongoing action of the formidable State Attorney General (SAG) of the Southern District of NY, Preet Bharara, casts a reputational shadow over the incumbent Novartis Chairman and CEO, who both had operational responsibilities at Novartis during the alleged period of widespread kickbacks."Further Details"Similar to GlaxoSmithKline plc (ADR) (NYSE: GSK) before it, Novartis faces a high probability of significant fines (in excess of $2 billion) as well as an additional punitive Corporate Integrity Agreement providing material risk to already lowered consensus Entresto (cardiovascular) estimates," analyst Baum wrote in a note to clients.The analyst cut his 2025 Entresto estimate to $2 billion from $10 billion.Related Link: Novartis Shares Downgraded, Leerink Says "Consensus Still Way Too High"The State Attorney General alleges "Novartis allowed kickbacks or inducements to prescribers of their cardiovascular drug through a stream of round table and education events, typically at restaurants," Baum elaborated.The analyst continued, "The provision of nine years' worth of records and salesmen testimony could indeed generate sufficient evidence to ensure a successful prosecution. The highest individual payment under the FCA was a $2 billion settlement from GSK in 2012 in relation to extensive off-label promotion over a prolonged period."Much more importantly, the DoJ imposed a strict CIA on GSK that continues to negatively impact the performance of GSK primary care portfolio, including the newly launched respiratory products (Breo and Anoro)."We think the issuance of a GSK-like CIA to Novartis would likely severely impact Novartis' earnings and valuation outlook given the important anticipated contribution of future Entresto revenues (cardiovascular disease)," Baum noted."It is possible that Novartis's decision to delay aggressive marketing of Entresto in the US was related to the ongoing SAG investigation," (3/29/2016)
Who owns Novartis AG stock?
Novartis AG's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (0.62%), Loomis Sayles & Co. L P (0.26%), State Street Corp (0.13%), Renaissance Technologies LLC (0.10%), Federated Investors Inc. PA (0.08%) and Dimensional Fund Advisors LP (0.05%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis.
Who sold Novartis AG stock? Who is selling Novartis AG stock?
Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, First Republic Investment Management Inc., Osterweis Capital Management Inc., Brown Advisory Inc., Scharf Investments LLC, Capital Guardian Trust Co. and Guardian Capital LP.
Who bought Novartis AG stock? Who is buying Novartis AG stock?
Novartis AG's stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Federated Investors Inc. PA, Loomis Sayles & Co. L P, Davis Selected Advisers, Edge Asset Management Inc., Van ECK Associates Corp, Thornburg Investment Management Inc. and Gratus Capital LLC. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis.
How do I buy Novartis AG stock?
Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Novartis AG stock cost?
One share of Novartis AG stock can currently be purchased for approximately $77.28.